Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JBZ-001 in Advanced Solid and Hematological Malignancies
NCT06801002Phase 1Recruiting
- Sponsor
- Jabez Biosciences
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JBZ-001 in solid tumor and non-Hodgkin lymphoma (NHL) (6 cohorts), sponsored by Jabez Biosciences. Primary endpoints: Adverse Events at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
JBZ-001
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06801002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801002.